The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...